DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase 2

Withdrawn

Conditions: Metastatic HER2-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Unresectable HER2-Negative Breast Carcinoma

Interventions: Drug: Alpelisib
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Procedure: Positron Emission Tomography

First Posted Date: 2023-08-01

Last Posted Date: 2024-03-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05967286

Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias

Recruiting

Conditions: Acute Lymphoblastic Leukemia
B Cell
Relapsed/Refractory

First Posted Date: 2023-08-01

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT05969002

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Phase 2

Recruiting

Conditions: Early-stage Mesothelioma
BRCA1-Associated Protein-1 (BAP1) Mutations
Mesothelioma
Subclinical Mesothelioma
Early-stage BAP1-associated Malignancies
Malignant Mesothelioma (MM)

Interventions: Drug: Decitabine/cedazuridine

First Posted Date: 2023-07-27

Last Posted Date: 2025-05-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT05960773

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

Phase 2

Withdrawn

Conditions: Chronic Hepatitis Delta

Interventions: Drug: Peginterferon Lambda

First Posted Date: 2023-07-20

Last Posted Date: 2024-05-23

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT05953545

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1

Recruiting

Conditions: Ovarian High Grade Serous Adenocarcinoma
Endometrial Carcinoma
Platinum-Resistant Ovarian Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Endometrioid Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Endometrial Low Grade Endometrioid Adenocarcinoma
Ovarian Low Grade Endometrioid Adenocarcinoma

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Electrocardiography
Procedure: Magnetic Resonance Imaging
Drug: Tuvusertib
Procedure: X-Ray Imaging

First Posted Date: 2023-07-18

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT05950464

Locations: 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

and more 11 locations

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2

Suspended

Conditions: Unresectable Merkel Cell Carcinoma
Locally Advanced Merkel Cell Carcinoma
Metastatic Merkel Cell Carcinoma
Refractory Merkel Cell Carcinoma
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

Interventions: Procedure: Biopsy Procedure
Drug: Avelumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Tuvusertib

First Posted Date: 2023-07-17

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05947500

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 47 locations

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2

Recruiting

Conditions: Breast Atypical Hyperplasia
Breast Carcinoma
Breast Ductal Carcinoma In Situ
Breast Lobular Carcinoma In Situ

Interventions: Drug: Acolbifene Hydrochloride
Procedure: Biospecimen Collection
Procedure: Mammography
Other: Questionnaire Administration
Procedure: Random Periareolar Fine-Needle Aspiration
Drug: Tamoxifen

First Posted Date: 2023-07-12

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT05941520

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 1 locations

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: KPT-8602
Drug: Inqovi

First Posted Date: 2023-06-26

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT05918055

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma, Primary Effusion

Interventions: Drug: Daratumumab SC

First Posted Date: 2023-06-18

Last Posted Date: 2025-03-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT05907759

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Phase 2

Recruiting

Conditions: GATA2
Immunodeficiency

Interventions: Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Post-Transplant Cyclophosphamide
Radiation: Total Body Irradiation
Procedure: Hematopoietic Cell Transplant
Drug: Briquilimab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-06-18

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT05907746

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy